Serum lipoprotein lipid concentrations (mmol/l), apolipoprotein AI and B (mg/dl), Lp(a) lipoprotein (mg/dl), and blood pressure (mm Hg) in 59 patients treated with simvastatin randomised to receive omega-3 PUFA (Omacor) or placebo for 24 weeks after which 46 patients received omega-3 PUFA for a further 24 weeks
| Treatment | None | Omega-3 PUFA concentrate | Omega-3 PUFA concentrate | Omega-3 PUFA concentrate | None | Placebo | Placebo | Omega-3 PUFA concentrate | ||
| Weeks | 0 | 12 | 24 | 48 | 0 | 12 | 24 | 48 | ||
| n | 30 | 30 | 29 | 25 | 29 | 27 | 26 | 21 | ||
| Serum triglycerides | 4.6 (2.2) | 3.3 (1.4)2-165 | 3.5 (1.8)2-165 | 3.0 (1.7)2-165 | 3.8 (2.2) | 3.9 (2.0) | 3.9 (2.5) | 2.9 (1.9)2-165 | ||
| Serum cholesterol | 5.6 (1.5) | 4.9 (1.2)2-150 | 5.0 (1.2)2-150 | 4.9 (0.9)2-160 | 6.2 (1.4) | 6.3 (1.5) | 6.4 (1.5) | 6.0 (1.4) | ||
| VLDL cholesterol | 1.0 (0.5) | 0.6 (0.5)2-160 | 0.6 (0.4)2-160 | 0.7 (0.5)2-160 | 0.9 (0.6) | 0.8 (0.6) | 0.8 (0.6) | 0.6 (0.6)2-160 | ||
| LDL cholesterol | 3.5 (1.4) | 3.1 (1.1) | 3.3 (1.2) | 2.8 (1.0)2-150 | 4.2 (1.6) | 4.2 (1.7) | 4.4 (1.7) | 3.7 (1.8) | ||
| HDL cholesterol | 1.1 (0.4) | 1.2 (0.4) | 1.0 (0.3) | 1.2 (0.4) | 1.1 (0.4) | 1.2 (0.5) | 1.3 (0.4) | 1.3 (0.5) | ||
| Apolipoprotein AI | 90 (14) | Not done | 84 (13) | 96 (20) | 89 (15) | Not done | 89 (13) | 95 (18) | ||
| Apolipoprotein B | 96 (31) | Not done | 95 (26) | 93 (24) | 110 (31) | Not done | 114 (33) | 108 (34) | ||
| Lp(a) lipoprotein | 10.5 (2.1–152.1) | Not done | 16.2 (1.9–99.1) | 15.5 (2.1–105.4) | 26 (6.7–178) | Not done | 38.5 (6.7–176) | 26.6 (5.9–176.4) | ||
| Systolic blood pressure | 129 (15) | Not done | 130 (22) | 127 (15) | 131 (20) | Not done | 130 (19) | 131 (20) | ||
| Diastolic blood pressure | 79 (8) | Not done | 78 (11) | 79 (8) | 79 (11) | Not done | 79 (10) | 81 (11) | ||